Pursuant to Regulation 30 of SEBI LODR Regulations, We hereby submit the updated Investor Presentation

PHARIII XUDIREHIN IIIDU$IRIEX lTD Head Office : 30'1, Aura Biplex, Premium Hetail Premises, 7, S.V, Hoad, Borivali (West), Mumbai - 400092 E-mail : compiiance@sudarshanpharma.com Website: vwvw.sudarshanpharma.com Board Line : +91'22-42221111 I 43331 1 11 I 422211 16 (100 line) r Qlp : 15.1496[/H2008P1C184997 s P II-/c s/s F. I 2026 -2027 I 49 Date: 18th August 2026 The Listing Department BSE Limited BSE Scrip Code: 543828 Phiroze Jeejeebhoy Towers, BSE Trading Symbol: SUDARSHAN Dalal Street, Mumbai - 400 001 ISIN: INE00TV01023 Sub: Investor Presentation - Disclosure pursuant to Regulation 30 of SEBI (Listing Obtigations And Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, In tcrms of Regulation 30 read with Para A of Parl A of Sohedule III to the SEBI (Listing Obligarions And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Invcstor Presentation. l{equcst you to take the same on your record. Iror. Sudarshan Pharma Industries l,imited fiLunrhAt Nirav Shah Compar-r1, Sccretary & C Irncl: As abovc Regd. Otf. : 301, Aura Biplex, Above Kalyan Jewellers, S,V. Hoad, Borivali (West), Mumbai - 400092, Sudarshan Pharma Industries Limited Innovating Chemistry, Empowering Health” INVESTOR PRESENTATION August 2026 E-mail :Compliance@sudarshanpharma.com Website:www.sudarshanpharma.com ContactNo:CS Niravshah:7700966328 COMPANY BACKGROUND & OVERVIEW SudarshanPharma IndustriesLimited | Investor Presentation ASpecialty Chemicals & Pharmaceutical Trading and Manufacturing Company 18Years Founded in 2008, Sudarshan Pharma Industries Limited (SPIL) is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products DiversifiedProducts The Company specializes in host of products from rock chemicals intermediates and API to finish formulations and fully integrated pharmaceutical and chemicals GlobalReach The company has marked its presence in India and Internationalmarkets.Itsproductshavebeenexportedto the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, andMENAregions. EsteemedClients Key clients in pharmaceutical formulations and specialty chemicals include Intas, Minova, Invision Life sciences, Omkar Pharma, SRF, Astral Pipes, DuPont,Reliance,BayerCorp,AkzoNobeletc SudarshanPharma IndustriesLimited | Investor Presentation Milestones 2008- 2011- 2013- 2015- 2017- 2010 2012 2014 2016 2018 • 2008-Expanded • Generic • Establishedour • Over5,000medical • Manufacturingof marketreachby formulations for footprintsin practitioners Nutraceuticals. importinghigh- institution supply, Gujarat,West associatedwith qualityraw NGOsand Bengal, SPIL. • BrandBrilliance materialsand wholesalemarket. Chhattisgarh,and AwardfromAsian products. UttarPradesh. • 7ownbranded Africanleadership • BrandedGeneric products foruminPharma. • 2009–Partnered formulationsin • Introducedbrands introduced withmanufacturers Maharashtra. inNewDrug successfullyin toscaleproduction DeliverySystem Vimac. andoptimizecosts. • 2010–Focusedon newproduct developmentand market-driven innovation. SudarshanPharma IndustriesLimited | Investor Presentation Milestones 2019- 2021- 2023- 2024- 2025- 2020 2022 2024 2025 2026 • *Nutraceuticals • IVD-Section Got • New unit • Incorporated • Proposed Plant project cost 50Cr. Govt. Order. development in Sudarshan Maven Allotment of FCCB is Rs. 2.5 Cr. And • Successfully Palghar. Pharma Private of 20 Million USD Rs. 1.15 Cr • erected oral liquid • Listed on the BSE Limited • Acquired capex for Machinery cost. • and capsule SME Platform on • Acquired Ratna Rs. 25.50 Crores • *Launch Hart Kit manufacturing March 23, 2023. Lifesciences & 51% from Srigen Loading Dose And unit at Palghar. • Developing new of Ishwari Lifesciences Hart Kit4. • AATMA NIRBHAR products like Healthcare. Private Limited BHARAT Vitamin B1 and • Opened subsidiary • Manufacturing of Vitamin B6, which in Poland Vitamin B1 & B6 will be the first Under Production time made in India Linked Incentive by us. (PLI) Schemes SudarshanPharama IndustriesLimited | Investor Presentation BusinessLayout ExistingBusinessLayout Thecompany isfocusingonincreasingmanufacturingcapabilitiesandhasstartedVerticalIntegrationforexpansioninthefollowingsegments: BrandedGenerics FinishedFormulation andF&OResearch & APIManufacturing Development andImport Intermediates forAPI ChemicalRaw Materialfor Pharmaceuticals Pharmabeginswith Asanorganization builtontheprinciplesofupwardintegrationwithinthepharmaceutical industry,wearecommitted todeliveringhigh-qualityproductsat affordable prices whileconsistentlyinvestinginin-houseR&D. SudarshanPharma IndustriesLimited | Investor Presentation Subsidiaries SUDARSHANPHARMAINDUSTRIES LTD. Wholly Owned Subsidiaries 51% Ownership Ratna Lifescience Pvt. Ltd. Life Science Chemical Sudarshan Industries Ishwari Healthcare Pvt. Ltd. Pvt. Ltd. INC, USA Existing Products: Existing Products: ExistingProducts: •Gemcitabine • Tanninextracts • Pharmaceuticals • PolyglycolicAcid Sutures Hydrochloride • Solvents • Antibiotics • Polypropylene Mesh •2,2-difluoro-2 – • Dyestuffs • Drugs, • Infant Feeding Tube •deoxycytidine-3, • Pigments • Medicines, • Thoracic Drainage Catheter 5-dibenzoate (T9) • Biological, •ImatinibMesylate • Neutraceuticals, •Capecitabine • Ayurvedic Intermediate (Cap-5) • Dietary SudarshanPharma IndustriesLimited | Investor Presentation Subsidiaries SUDARSHANPHARMAINDUSTRIES LTD. WhollyOwned Subsidiaries 70% Ownership Sudarshan Pharma Cibachem General Trading Sudarshan Maven Sudarshan Pharma Industries Private Limited, LLC, Dubai Pharma Private Limited Lifescience Private Singapore Limited Trading activities of all Existing Products: The Company is engaged types of goods and in wholesale trading • Pharmaceuticals, Existing Products: ancillary insurance activities across various • API & Intermediates, • Pharmaceuticals activities categories, including • Antibiotics,Drugs, • Antibiotics, Drugs, basic industrial chemicals. Medicines, Medicines • Biological • Biological Products neutraceuticals. SudarshanPharma IndustriesLimited | Investor Presentation Key Products SPEKeCyIAPLroIdTuYcGtsREEN CHEMICALS Acetonitrile Tetrahydrofuran (THF) 1, 4-Dioxane DMF/DMSO NMP(N-Methyl-2- Metaxylene N-Heptane Diethanolamine pyrrolidone) PHARMADIVISION Outof96products,56areregisteredunderthe“R”Trade Mark. • SPILhas introducedanoveldrugdeliverysystem underthe LoveBird“R”Brand,featuringamouth-dissolvingstripwith5productsinthiscategory. • ForthefirsttimeinIndia,SPILhaslaunchedspecialtyproductsinthecardiacsegment,includingthe HARTKITLD, whichprovideslife-savingdrugsfor firstaidinheartattacks. • Theproduct“SETDOWN”,introducedforthefirsttimeinIndia,combines allopathyandayurvedatoenablefasterrecoveryfromconstipation. • Top-SellingBrandsintheIndianMarket include:METFOCAL,PULMORELIEFAX,RDMACDSR,SETDOWN, ENAMOLSPHemD3,JIVANKIT (ImmunityBooster),and InfortQ-10,amongothers. SudarshanPharma IndustriesLimited | Investor Presentation Key Products PERFORMANCE CHEMICALS & INTERMEDIATE CAMPAIGN BASIS • Specialize Performance Chemials • Sesamol (3,4-(Methylenedioxy)phenol) CAS. 533-31-3 (Having Patent Filled on April 16th 2026). • 4-((4-Fluorophenyl)imino)methyl)phenol CAS. 3382-63-6 • (S)-3-[5-(4-Fluorophenyl)-1,5-dioxopentyl]-4-phenyloxazolidin-2-one CAS. 189028-93-1 • (S)-3-((2R,5S)-5-(4-Fluorophenyl)-2-((S)-((4-fluorophenyl)amino)(4-((trimethylsilyl)oxy)phenyl)methyl)-5- ((trimethylsilyl)oxy)pentanoyl)-4-phenyloxazolidin-2-one CAS. 272778-12-8 • Meldrums acid CAS. 2033-24-1 • 4-Nitro benzene sulfonyl chloride CAS. 98-74-8 • CIS LACTUM CAS. 189028-93-1 • 2,2-Dimethyl-1,2-dimethyl-4,6-dione CAS.2033-24-1 • 3-Morpholino-2-cyanoacrylamide CAS. 25229-97-4 • 3-Aminopyrazole-4-carboxamide Hemisulphate CAS. 27511-79-1 • 4-(chlorosulfonyl)benzoic acid CAS. 10130-89-9 • Piperidine-2-carbonyl chloride Hydrochloride CAS. 98626-58-5 • N-(2,6-dimethylphenyl) piperidine-2-carxamide hydrochloride CAS. 65797-42-4 • 1-Butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide CAS. 27262-48-2 • (S)-pip [Showing first 8,000 characters — download PDF for full document]